Piper Sandler Maintains Overweight on AnaptysBio, Lowers Price Target to $93
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $95 to $93.
Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $95 to $93.